Bellicum files for IPO

Bellicum Pharmaceuticals Inc. (Houston, Texas) filed to raise up to $115 million in an IPO on NASDAQ underwritten by Jefferies; Citigroup; and Piper Jaffray.

The company is conducting multiple Phase I/II trials of BPX-501, a therapy comprising T cells containing the company's CaspaCIDe gene that is designed to eliminate donor T cells associated with toxicity in hematopoietic stem cell transplant (HSCT) patients. Bellicum's BPX-201, which consists of genetically modified, autologous dendritic cells targeting prostate cancer cells, is in a Phase I trial to treat metastatic castration-resistant prostate cancer (CRPC). ...